Possibilities and shortcomings of maintenance therapy in gastroesophageal reflux disease

被引:5
作者
Tytgat, GNJ [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands
关键词
gastroesophageal reflux disease; H-2-receptor antagonists; prokinetics; proton pump inhibitors;
D O I
10.1159/000018685
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
An overview is given of the current possibilities and shortcomings of medical therapy in reflux disease. With H-2-receptor antagonists and prokinetics, roughly 60% of the patients can be maintained in remission; with proton pump inhibitors, remission can be maintained in approximately 90%, Whether there is a specific symptom pattern that benefits from cisapride is insufficiently evaluated. H-2-receptor antagonists insufficiently reduce food-stimulated acid secretion and suffer from a degree of tachyphylaxis. Proton pump inhibitors suffer from acid rebound and occasionally cannot prevent nocturnal acid breakthrough, In general, medical intractability is virtually nonexistent with the current pharmaceutical possibilities and is therefore no longer per se an indication for surgery.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 20 条
[1]  
Boeckxstaens GE, 1998, AM J GASTROENTEROL, V93, P1823
[2]   Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: A meta-analysis of long-term omeprazole trials [J].
Carlsson, R ;
Galmiche, JP ;
Dent, J ;
Lundell, L ;
Frison, L .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (03) :473-482
[3]   Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis [J].
Chiba, N ;
DeGara, CJ ;
Wilkinson, JM ;
Hunt, RH .
GASTROENTEROLOGY, 1997, 112 (06) :1798-1810
[4]   Omeprazole produces parietal cell hypertrophy and hyperplasia in humans [J].
Driman, DK ;
Wright, C ;
Tougas, G ;
Riddell, RH .
DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (10) :2039-2047
[5]  
ElOmar E, 1996, AM J GASTROENTEROL, V91, P355
[6]   Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease [J].
Hatlebakk, JG ;
Berstad, A .
CLINICAL PHARMACOKINETICS, 1996, 31 (05) :386-406
[7]   The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease [J].
Hatlebakk, JG ;
Johnsson, F ;
Vilien, M ;
Carling, L ;
Wetterhus, S ;
Thogersen, T .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (11) :1100-1106
[8]   Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis [J].
Hatlebakk, JG ;
Berstad, A .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1996, 31 (10) :954-958
[9]  
Hendel J, 1996, EUR J GASTROEN HEPAT, V8, P417
[10]   Choice of long-term strategy for the management of patients with severe esophagitis: A cost-utility analysis [J].
Heudebert, GR ;
Marks, R ;
Wilcox, CM ;
Centor, RM .
GASTROENTEROLOGY, 1997, 112 (04) :1078-1086